Skip to main content
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2011 Feb 11;46:21–25. [Article in Spanish] doi: 10.1016/S0300-2896(10)70042-9

Exacerbación de la EPOC

Exacerbation of chronic obstructive pulmonary disease

Myriam Calle Rubio 1,, Beatriz Morales Chacón 1, Juan Luis Rodríguez Hermosa 1
PMCID: PMC7130601  PMID: 21316546

Abstract

Exacerbations of chronic obstructive pulmonary disease (COPD) are considered to be episodes of instability that favor disease progression, reduce quality of life, increase the risk of death and cause substantial healthcare resource use. These exacerbations are due to bacterial and viral infections and environmental stressors. However, other concomitant diseases such as heart disease, other lung diseases (e.g. pulmonary embolism, aspiration or pneumothorax) and other systemic processes can trigger or complicate these exacerbations. The two factors with the greatest influence on the physiopathology of exacerbations are dynamic overinflation and local and systemic inflammation. In most patients, drug treatment includes short-acting bronchodilators, systemic corticosteroids and antibiotics. Hypoxemic respiratory failure requires controlled oxygen therapy. In hypercapnic respiratory failure, non-invasive positive pressure ventilation may allow time to be gained until other treatments begin to take effect and can thus avoid endotracheal intubation. The use of non-invasive mechanical ventilation should never delay intubation, if indicated. Hospital discharge criteria are based on both clinical and gasometric stabilization and on the patient's ability to manage his or her disease at home. Hospitalization at home can be a treatment option in COPD exacerbations and is as effective as conventional hospitalization.

Keywords: COPD, exacerbation, infection, antibiotics, treatment

Bibliografía

  • 1.Soler-Cataluña J.J., Sánchez L., Latorre M., Alamar J., Román P., Perpiñá M. Impacto asistencial hospitalario de la EPOC. Peso específico del paciente con EPOC de alto consumo sanitario. Arch Bronconeumol. 2001;37:375–381. doi: 10.1016/s0300-2896(01)78818-7. [DOI] [PubMed] [Google Scholar]
  • 2.Seemungal T.A.R., Donaldson G.C., Paul E.A., Bestall J.C., Jeffries D.J., Wedzicha J.A. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157:1418–1422. doi: 10.1164/ajrccm.157.5.9709032. [DOI] [PubMed] [Google Scholar]
  • 3.Doll H., Miravitlles M. Quality of life in acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease: A review of the literature. Pharmacoeconimics. 2005;23:345–363. doi: 10.2165/00019053-200523040-00005. [DOI] [PubMed] [Google Scholar]
  • 4.Soler-Cataluña J.J., Martínez-García M.A., Román Sánchez P., Salcedo E., Navarro M., Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60:925–931. doi: 10.1136/thx.2005.040527. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Rodriguez-Roisín R. Toward a consensus definition for COPD exacerbations. Chest. 2000;117(5 Suppl 2):398S–401S. doi: 10.1378/chest.117.5_suppl_2.398s. [DOI] [PubMed] [Google Scholar]
  • 6.Álvarez-Gutiérrez F.J., Miravitlles M., Calle M., Gobartt E., López F., Martín A y grupo de estudio EIME. Impacto de la EPOC en la vida diaria de los pacientes. Resultados del estudio multicéntrico EIME. Arch Bronconeumol. 2007;43:64–72. doi: 10.1016/s1579-2129(07)60026-3. [DOI] [PubMed] [Google Scholar]
  • 7.Miravitlles M. Tratamiento farmacológico de las agudizaciones infecciosas en la EPOC. Arch Bronconeumol. 2007;43(Supl 4):18–26. [Google Scholar]
  • 8.Rosell A., Monsó E., Soler N., Torres F., Angrill J., Riise G. Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease. Arch Intern Med. 2005;165:891–897. doi: 10.1001/archinte.165.8.891. [DOI] [PubMed] [Google Scholar]
  • 9.Soler-Cataluña J.J., Martínez García M.A. Enfermedad pulmonar obstructiva crónica: tratamiento de las exacerbaciones. In: Álvarez-Sala J.l., Casan Clará P., Rodríguez de Castro F., Rodríguez Hermosa J.L., Villena Garrido V., editors. Neumología clínica. Elsevier; Madrid: 2010. pp. 197–204. [Google Scholar]
  • 10.Celli B.R., MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23:932–946. doi: 10.1183/09031936.04.00014304. [DOI] [PubMed] [Google Scholar]
  • 11.Anthonisen N.R., Manfreda J., Warren C.P., Hershfield E.S., Harding G.K., Nelson N.A. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106:196–204. doi: 10.7326/0003-4819-106-2-196. [DOI] [PubMed] [Google Scholar]
  • 12.Miravitlles M., Monsó E., Mensa J., Aguarón Pérez J., Barberán J., Bárcena Caamaño M. Tratamiento antimicrobiano de la agudización de la EPOC. Arch Bronconeumol. 2008;44:100–108. doi: 10.1016/s1579-2129(08)60013-0. [DOI] [PubMed] [Google Scholar]
  • 13.Aaron S.D., Vandemheen K.L., Hebert P., Dales R., Stiell I.G., Ahuja J. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med. 2003;348:2618–2625. doi: 10.1056/NEJMoa023161. [DOI] [PubMed] [Google Scholar]
  • 14.Peces-Barba G., Barberá J.A., Agustí A., Casanova C., Casas A., Izquierdo J.L. Guía clínica SEPAR-ALAT de diagnóstico y tratamiento de la EPOC. Arch Bronconeumol. 2008;44:100–108. [PubMed] [Google Scholar]

Articles from Archivos De Bronconeumologia are provided here courtesy of Elsevier

RESOURCES